1-3 of 3
Christine Brozo
Close
Sort by
Journal Articles

Initial Treatment with Bortezomib (Velcade ® ), Doxil ® , and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)

Andrzej Jakubowiak, MD, PhD, Tara Kendall, PA, Ammar Al-Zoubi, MD, Yasser Khaled, MD, Shin Mineishi, MD, Christine Brozo, Erica Campagnaro, MD, Moshe Talpaz, Mark S. Kaminski, MD
Journal: Blood
Blood (2008) 112 (11): 3713.
https://doi.org/10.1182/blood.V112.11.3713.3713
Published: 2008
Journal Articles

Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

Andrzej Jakubowiak, MD, PhD, Paul Richardson, MD, Todd M. Zimmerman, MD, Melissa Alsina, MD, Jonathan L. Kaufman, MD, Colleen Harvey, Christine Brozo, PA, Tara Kendall, PA, Amanda McAllister, Teru Hideshima, MD, PhD, Peter Sportelli, Lesa Gardner, RN, Kenneth C. Anderson, MD, Kathy Giusti, MBA
Journal: Blood
Blood (2008) 112 (11): 3691.
https://doi.org/10.1182/blood.V112.11.3691.3691
Published: 2008
Journal Articles

Serum Free Light Chain Analysis Improves Monitoring of Multiple Myeloma Patients Receiving First-Line Therapy with the Combination of Velcade, Doxil, and Dexamethasone (VDD).

Daniel Lebovic, MD, Tara Kendall, PA-C, Christine Brozo, PA-C, Amanda McAllister, BS, Malathi Hari, PhD, Sairah Alvi, PhD, Ewan J.D. Robson, PhD, Andrzej J. Jakubowiak, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2736.
https://doi.org/10.1182/blood.V110.11.2736.2736
Published: 2007